Vaishali Pharma (VAISHALI) Q3 24/25 earnings summary

Executive summary

• Un-audited financial results for the quarter and nine months ended December 31, 2024, were approved by the Board and reviewed by statutory auditors, with no material misstatements identified.

Financial highlights

• Revenue from operations for Q3 FY25 was ₹2,791.43 lakhs, nearly flat year-over-year (₹2,789.54 lakhs in Q3 FY24).

• Net profit for Q3 FY25 was ₹144.26 lakhs, down from ₹211.19 lakhs in Q3 FY24.

• Total income for the nine months ended December 31, 2024, was ₹6,898.12 lakhs, up from ₹5,501.19 lakhs in the prior year period.

• Net profit for the nine months was ₹510.99 lakhs, compared to ₹540.14 lakhs for the same period last year.

• Basic and diluted EPS for Q3 FY25 stood at ₹1.11, compared to ₹1.99 in Q3 FY24.

Outlook and guidance

• Financial statements were prepared in accordance with Indian Accounting Standards and reviewed by the Audit Committee and Board.